Glen Weiss
Fractional Chief Medical Officer (Fractional CMO) | Clinical Development Strategy | Oncology Drug Development | Medical Expert Witness (Oncology)
- Role
- Chief Medical Officer at Mbiomics Gmbh
- Location
- Boston, MA, US
- LinkedIn followers
- 500 followers
About Glen Weiss
Early-stage biotechs and clinical-stage pharma often have brilliant science — but translating it into regulatory-ready trials, robust safety frameworks, and investor-ready clinical strategy is a challenge. I help founders bridge that gap as a Fractional Chief Medical Officer (Fractional CMO).As a fractional CMO and clinical development strategist, I partner with companies to:• Design and execute Phase I/II trials efficiently and safely • Build medical and regulatory strategy for IND/CTA readiness • Establish safety oversight and trial governance • Provide fractional medical leadership to guide product lifecycle decisions from first-in-human to early proof of concept and through market entry I bring 20+ years of experience as a medical oncologist, physician-scientist, and industry executive, including:• Director of Phase I Clinical Research at Beth Israel Deaconess / Harvard Medical School • Site PI on >50 Phase I/II trials, including chemotherapy, small molecules, and biologics.•Industry medical director/executive with hands-on experience in CAR-T, ADCs, PROTACs, and advanced oncology therapeutics • Advisory board member and medical monitor for numerous startups and research programs • Additionally, I serve as an expert witness/reviewer in medical malpractice and patent litigation cases (including NY, IL, IN, TX, DE) Specialties: Fractional Chief Medical Officer, Fractional CMO, Clinical Development Strategy, Phase I/II Trials, Life Cycle Management, Regulatory Readiness (IND/CTA), Small Molecules, Biologics, CAR-T, ADCs, PROTACs, Medical Monitoring, Medical Expert Witness, Healthtech AI.If you’re building a biotech or digital health venture and need interim medical leadership without committing to a full-time hire, let’s connect. DM me to explore how I can help accelerate your clinical programs safely and strategically.Google Scholar Publications: https://scholar.google.com/citations?view_op=search_authors & mauthors=glen+weiss & hl=en & oi=ao FCOI last 24 months: Employment/Advisory/consultant role: Qubim, IGC, Angiex, Phoenix Cancer Support Network, Imaging Endpoints, SUN Pharma, Kymera, Maverix Medical, Accent Therapeutics, mbiomics, Bantam Pharmaceutical, Avenio.AI, Converge Bio, MiRanostics Consulting. Ownership interest: Circulogene, Quibim, MiRanostics Consulting, Stealth, MRNA, AGEN.
Experience
Chief Medical Officer
Mar 2025 — Present
Fractional
Education
W. P. Carey School of Business – Arizona State University
Master of Business Administration (MBA), Finance, General
2012 — 2013
Rutgers University
BA, Biology
Sackler School of Medicine
MD, Medicine
Skills
- Medical Research
- Mirna
- Translational Medicine
- Molecular Genetics
- Clinical Research
- Immunology
- Assay Development
- Medicine
- Phase I
- Immunohistochemistry
- Drug Discovery
- Laboratory
- Drug Development
- Cancer
- Pharmacology
- Molecular Biology
- Medical Writing
- Clinical Trials
- Genetics
- Translational Research
- Oncology
- Biotechnology
- Personalized Medicine
- Genomics
- Molecular Diagnostics
- Lung Cancer
- Biomarkers
- Clinical Development
- Cancer Research
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.